Original Literature | Model OverView |
---|---|
Publication
Title
A novel negative regulator for IL-1 receptor and Toll-like receptor 4.
Affiliation
Division of Immunology, Infection and Inflammation, University of Glasgow,Glasgow G11 6NT, UK. fyl1h@clinmed.gla.ac.uk
Abstract
The Toll-IL-1 receptor (TIR) superfamily, defined by the presence of anintracellular TIR domain, initiates innate immunity via NF-kappaB activation,leading to production of proinflammatory cytokines. ST2 is a member of the TIRfamily that does not activate NF-kappaB and has been suggested as an importanteffector molecule of type 2 T helper cell responses. We have recentlydemonstrated that the membrane bound form of ST2 (ST2L) negatively regulatedIL-1RI and TLR4 but not TLR3 signaling by sequestrating the adaptors MyD88 andMal. In contrast to wild-type mice, ST2 deficient mice failed to developendotoxin tolerance. Thus, ST2 suppresses IL-1R and TLR4 signaling via MyD88-and Mal-dependent pathways and modulates innate immunity. The results provide amolecular explanation for the role of ST2 in T(H)2 responses since inhibition ofTLRs will promote a T(H)2 response and also identify ST2 as a key regulator ofendotoxin tolerance.
PMID
15585304
|
Entity
IL-6
--
G010262
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93248
10
infinite
0
TRANSFAC | G010262 |
--
IL-12 p40
--
G010657
cso30:c:mRNA
cso30:i:CC_CellComponent
--
csml-variable:Double
m93589
10
infinite
0
TRANSFAC | G010657 |
--
NF-kappaB
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m14
10
infinite
0
TRANSPATH | MO000000058 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
IL-6
--
MO000007384
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m871
10
infinite
0
InterPro | IPR003573 |
TRANSPATH | MO000007384 |
--
IL-1alpha
--
MO000016589
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1584
10
infinite
0
InterPro | IPR008996 |
TRANSPATH | MO000016589 |
--
IL-1beta
--
MO000016597
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1591
10
infinite
0
TRANSPATH | MO000016597 |
--
IL-12
--
MO000017265
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2121
10
infinite
0
TRANSPATH | MO000017265 |
--
MAL
--
MO000068831
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m43675
10
infinite
0
TRANSPATH | MO000068831 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
ligand: TLR: MyD88
--
e11
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m11
0
infinite
0
--
ligand: TLR: MyD88: IRAK-1: IRAK-4
--
e12
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m12
0
infinite
0
--
IRAK-1: IRAK-4: TRAF6
--
e13
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m13
0
infinite
0
--
NF-kappaB{activated}
--
e17
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m19
10
infinite
0
TRANSPATH | MO000000058 |
--
proinflammatory protein
--
e18
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m22
0
infinite
0
--
proinflammatory protein
--
e19
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m23
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
LPS: TLR4
--
e20
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m24
0
infinite
0
--
LPS: TLR4: MAL
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0
infinite
0
--
csml-variable:Double
m26
0
infinite
0
--
CpG DNA: TLR9
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m27
0
infinite
0
--
Pam3Cys-SK4: TLR2
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m28
0
infinite
0
--
Lp: TLR2
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m29
0
infinite
0
--
csml-variable:Double
m30
0
infinite
0
--
Lp: TLR2: MAL
--
e27
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m31
0
infinite
0
--
ST2
--
e28
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m32
0
infinite
0
--
csml-variable:Double
m33
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
ligand: TLR: MyD88: IRAK-1: IRAK-4{activated}
--
e30
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m34
0
infinite
0
--
IRAK-1: IRAK-1
--
e31
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m35
0
infinite
0
--
ligand: ST2
--
e32
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m36
0
infinite
0
--
ST2 ligand
--
e33
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m37
0
infinite
0
--
ligand: ST2: MAL
--
e34
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m38
0
infinite
0
--
ligand: ST2: MAL: MyD88
--
e35
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m39
0
infinite
0
--
IL-1: IL-1R1
--
e36
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m40
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
TLR ligand
--
e5
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m5
0
infinite
0
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
ligand: TLR
--
e6
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m6
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m3962*m5*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c32 : 1
stoichiometry:c36 : 1
stoichiometry:c28 : 1
m22*m18*0.1
nodelay
--
0
PMID: 15585304 These molecules in turn promote the production of many proinflammatory proteins and enhance immune reactivity.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c30 : 1
stoichiometry:c35 : 1
stoichiometry:c27 : 1
m22*m17*0.1
nodelay
--
0
PMID: 15585304 These molecules in turn promote the production of many proinflammatory proteins and enhance immune reactivity.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c33 : 1
stoichiometry:c37 : 1
stoichiometry:c29 : 1
m22*m19*0.1
nodelay
--
0
PMID: 15585304 These molecules in turn promote the production of many proinflammatory proteins and enhance immune reactivity.
p13
p13
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c46 : 1
stoichiometry:c38 : 1
m93248*m1584*0.1
nodelay
--
0
PMID: 15585304, Although macrophages from wild-type (WT) mice produced minimal amounts of IL-6, IL-12 and Tumour necrosis factor (TNF) in response to IL-1alpha and IL-1beta, those from ST2-deficient mice produced large amounts of these cytokines under identical culture conditions.
p14
p14
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c41 : 1
stoichiometry:c48 : 1
stoichiometry:c39 : 1
m93248*m1591*0.1
nodelay
--
0
PMID: 15585304, Although macrophages from wild-type (WT) mice produced minimal amounts of IL-6, IL-12 and Tumour necrosis factor (TNF) in response to IL-1alpha and IL-1beta, those from ST2-deficient mice produced large amounts of these cytokines under identical culture conditions.
p15
p15
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c44 : 1
stoichiometry:c47 : 1
stoichiometry:c42 : 1
m93589*m1584*0.1
nodelay
--
0
PMID: 15585304, Although macrophages from wild-type (WT) mice produced minimal amounts of IL-6, IL-12 and Tumour necrosis factor (TNF) in response to IL-1alpha and IL-1beta, those from ST2-deficient mice produced large amounts of these cytokines under identical culture conditions.
p16
p16
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c45 : 1
stoichiometry:c49 : 1
stoichiometry:c43 : 1
m93589*m1591*0.1
nodelay
--
0
PMID: 15585304, Although macrophages from wild-type (WT) mice produced minimal amounts of IL-6, IL-12 and Tumour necrosis factor (TNF) in response to IL-1alpha and IL-1beta, those from ST2-deficient mice produced large amounts of these cytokines under identical culture conditions.
p17
p17
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c50 : 1
stoichiometry:c52 : 1
stoichiometry:c54 : 1
m1584*m93309*0.1
nodelay
--
0
PMID: 15585304, Although macrophages from wild-type (WT) mice produced minimal amounts of IL-6, IL-12 and Tumour necrosis factor (TNF) in response to IL-1alpha and IL-1beta, those from ST2-deficient mice produced large amounts of these cytokines under identical culture conditions.
p18
p18
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c51 : 1
stoichiometry:c53 : 1
stoichiometry:c55 : 1
m1591*m93309*0.1
nodelay
--
0
PMID: 15585304, Although macrophages from wild-type (WT) mice produced minimal amounts of IL-6, IL-12 and Tumour necrosis factor (TNF) in response to IL-1alpha and IL-1beta, those from ST2-deficient mice produced large amounts of these cytokines under identical culture conditions.
p19
p19
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c57 : 1
stoichiometry:c58 : 1
m3961*m155666*0.1
nodelay
--
0
PMID: 15585304 Macrophages from ST2-deficient mice also produced significantly more IL-6 and IL-12 than cells from the WT mice when stimulated with LPS, a ligand of TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c5 : 1
stoichiometry:c6 : 1
m6*m1572*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
p20
p20
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c60 : 1
stoichiometry:c63 : 1
stoichiometry:c59 : 1
m93248*m24*0.1
nodelay
--
0
PMID: 15585304 Macrophages from ST2-deficient mice also produced significantly more IL-6 and IL-12 than cells from the WT mice when stimulated with LPS, a ligand of TLR4.
p21
p21
cso30:i:ME_Translation
cso30:i:CC_Nucleoplasm
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c62 : 1
stoichiometry:c64 : 1
stoichiometry:c61 : 1
m93589*m24*0.1
nodelay
--
0
PMID: 15585304 Macrophages from ST2-deficient mice also produced significantly more IL-6 and IL-12 than cells from the WT mice when stimulated with LPS, a ligand of TLR4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c65 : 1
stoichiometry:c67 : 1
stoichiometry:c66 : 1
m24*m43675*0.1
nodelay
--
0
PMID: 15585304, 11544529, 12447441 A similar effect was observed following overexpression of the TIR domain-containing adaptor Mal, which is involved in signaling from TLR4 and TLR2.
p23
p23
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c73 : 1
stoichiometry:c76 : 1
stoichiometry:c74 : 1
stoichiometry:c79 : 1
m3964*m2549*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c68 : 1
stoichiometry:c69 : 1
stoichiometry:c70 : 1
m19828*m26*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c71 : 1
stoichiometry:c75 : 1
stoichiometry:c72 : 1
m3964*m30*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c77 : 1
stoichiometry:c78 : 1
m43675*m29*0.1
nodelay
--
0
PMID: 15585304, 11544529, 12447441 A similar effect was observed following overexpression of the TIR domain-containing adaptor Mal, which is involved in signaling from TLR4 and TLR2.
p27
p27
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c85 : 1
stoichiometry:c86 : 1
stoichiometry:c82 : 1
m93248*m27*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
p28
p28
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c87 : 1
stoichiometry:c81 : 1
m93248*m29*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
p29
p29
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c88 : 1
stoichiometry:c80 : 1
m93248*m28*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c10 : 1
stoichiometry:c101 : 1
stoichiometry:c9 : 1
m11*m184*m17258*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2. PMID: 15585304, 12538665 MyD88s, a splice variant of MyD88, prevents IRAK-4 recruitment.
p30
p30
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c96 : 1
stoichiometry:c90 : 1
m28*m93589*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
p31
p31
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c92 : 1
stoichiometry:c97 : 1
stoichiometry:c91 : 1
m27*m93589*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
p32
p32
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c93 : 1
stoichiometry:c95 : 1
stoichiometry:c89 : 1
m29*m93589*0.1
nodelay
--
0
PMID: 15585304 A similar elevation of proinflammatory cytokine production was observed when the cells were stimulated with BLP (bacterial lipoprotein, Pam3Cys-SK4, ligand for TLR2), and CpG (ligand for TLR9).
p33
p33
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c99 : 1
stoichiometry:c100 : 1
stoichiometry:c98 : 1
m32*m155666*0.1
nodelay
--
0
PMID: 15585304 However, when the cells were cultured with LPS, ST2 was clearly detected by 4 h and sustained for at least 48 h.
p34
p34
cso30:i:ME_Dissociation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c107 : 1
stoichiometry:c102 : 1
stoichiometry:c11 : 1
m34*0.1
nodelay
--
0
PMID: 15585304, 12150927 IRAK-M also interferes with IRAK function by preventing dissociation of IRAK from the signaling complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c105 : 1
m12*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c108 : 1
stoichiometry:c109 : 1
stoichiometry:c110 : 1
m22456*m37*0.1
nodelay
--
0
PMID: 15585304 ST2 appears to exert its negative regulatory function on IL-1RI and TLR4 mediated NF-kappaB activation via sequestrating TLR proximal signaling components, MyD88 and Mal.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c113 : 1
stoichiometry:c112 : 1
m36*m43675*0.1
nodelay
--
0
PMID: 15585304 ST2 appears to exert its negative regulatory function on IL-1RI and TLR4 mediated NF-kappaB activation via sequestrating TLR proximal signaling components, MyD88 and Mal.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c114 : 1
stoichiometry:c116 : 1
stoichiometry:c115 : 1
m38*m1572*0.1
nodelay
--
0
PMID: 15585304 ST2 appears to exert its negative regulatory function on IL-1RI and TLR4 mediated NF-kappaB activation via sequestrating TLR proximal signaling components, MyD88 and Mal.
p39
p39
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c117 : 1
stoichiometry:c119 : 1
stoichiometry:c120 : 1
stoichiometry:c118 : 1
m14*m25*0.1
nodelay
--
0
PMID: 15585304 ST2 appears to exert its negative regulatory function on IL-1RI and TLR4 mediated NF-kappaB activation via sequestrating TLR proximal signaling components, MyD88 and Mal.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c104 : 1
stoichiometry:c13 : 1
m183*m35*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
p40
p40
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c121 : 1
stoichiometry:c122 : 1
stoichiometry:c124 : 1
stoichiometry:c123 : 1
m40*m14*0.1
nodelay
--
0
PMID: 15585304 ST2 appears to exert its negative regulatory function on IL-1RI and TLR4 mediated NF-kappaB activation via sequestrating TLR proximal signaling components, MyD88 and Mal.
p41
p41
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c127 : 1
stoichiometry:c126 : 1
m69*m39*0.1
nodelay
--
0
PMID: 15585304 ST2 is able to activate MAP kinases but not NF-kappaB.
p5
p5
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c14 : 1
stoichiometry:c22 : 1
stoichiometry:c15 : 1
m20*m13*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
p6
p6
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c16 : 1
stoichiometry:c23 : 1
stoichiometry:c17 : 1
m21*m13*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
p7
p7
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c18 : 1
stoichiometry:c24 : 1
stoichiometry:c19 : 1
m16*m13*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
p8
p8
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c20 : 1
stoichiometry:c25 : 1
stoichiometry:c21 : 1
m14*m13*0.1
nodelay
--
0
PMID: 15585304, 12467243 These adaptors are recruited to receptor TIR domains and initiate signaling processes through IL-1R-associated kinases (IRAKs) and the adaptor molecule TRAF-6, which leads to activation of four protein kinase cascades, culminating in the activation of NF-kappaB and the MAP kinases p38, JNK and ERK1/2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c34 : 1
stoichiometry:c26 : 1
m22*m15*0.1
nodelay
--
0
PMID: 15585304 These molecules in turn promote the production of many proinflammatory proteins and enhance immune reactivity.
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--